Flagship merges Cellarity, Etiome and Empress into AI drug discovery company Etcelera

Flagship Pioneering announced on 29 October 2026 that it has formed Etcelera by merging the platforms of three of its portfolio companies, Cellarity, Etiome and Empress Therapeutics, and pairing them with Flagship's own AI unit¹. Ad Rawcliffe, formerly chief executive of Adaptimmune and a GSK veteran, leads the new company².

What Flagship is combining

Each of the three businesses brings a different layer of biology. Cellarity worked on reading and correcting the state of whole cells, Etiome on identifying the disease stage and patients at which to intervene, and Empress on industrial multi-omics for target deconvolution and causal validation¹. Etcelera says the merged platform rests on more than 20 years of combined data, a foundation model trained on data from 150 million cells, which Flagship describes as the largest in the industry, and more than 30 proprietary AI prediction models¹.

The stated aim is to predict how a small molecule will behave in patients before it reaches the clinic. Alec Reynolds, Etcelera's chairman and a senior partner at Flagship, said: "Approximately 50 percent of drug candidates that reach Phase 2 fail because the industry lacks causal intelligence"¹. Rawcliffe told BioPharma Dive that he sees the company's use of "perturbation data", which records how cells respond when a gene is silenced or a chemical is added, as one of its advantages².

Etcelera starts with programmes in haematology, including myelofibrosis and essential thrombocythemia, in metabolism, including partnered work in MASH, and in immunology¹. Cellarity's clinical-stage sickle cell disease molecule, CLY-124, will not move into Etcelera and is being developed by a separate asset company¹².

What it means for the market

For large pharma, the immediate relevance is partnering. Etcelera keeps the 2022 alliance between Novo and Cellarity to find a small molecule for MASH, and Rawcliffe said a second alliance with a large drugmaker he did not name is in the works². He said the company wants partners with deep expertise in a disease or therapy area, and Etcelera lists data services alongside its own medicines as a line of business¹².

For investors, the deal is a consolidation rather than a new raise. No new funding came with the launch, and the three predecessor companies had raised $374 million in venture capital before the merger, money Rawcliffe said will carry the business further². BioPharma Dive places the move against a mixed backdrop: several AI-built biotechs have struggled on public markets, while private investment in AI drug discovery has accelerated in 2026, with Iambic Therapeutics recently going public².

For competitors, Etcelera joins a crowded field of companies claiming that computation can raise the odds of clinical success. Its pitch rests on causal biology and perturbation data at cell level rather than on molecular design alone¹².

Caveats

The claims about better odds of clinical success come from the company and Flagship, and neither source presents clinical evidence that the platform outperforms conventional discovery¹². BioPharma Dive notes the wider criticism that AI drug discovery companies may be overstating their potential and underestimating the complexity of human biology². The launch programmes are named only by disease area, with no stage of development given, and the identity and terms of the second pharma alliance have not been disclosed¹².